A Multi-center, Placebo-controlled, Multiple Dose, Study of the Safety and Pharmacokinetics and Pharmacodynamics of INX-08189 Dosed Either QD, BID or Adjunctively With Ribavirin, and a Study of the Food Effect, in Chronically-infected Genotype 1 HCV, Treatment-naive Subjects.
Phase of Trial: Phase I/II
Latest Information Update: 29 Jun 2016
At a glance
- Drugs BMS 986094 (Primary) ; INX 005; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- 29 May 2012 Actual end date (1 May 2012) added as reported by ClinicalTrials.gov.
- 29 May 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 30 Nov 2011 Results reported in an Inhibitex media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History